• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测非酒精性脂肪性肝病(NAFLD)进展的因素。

Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).

作者信息

Parameswaran Madhangi, Hasan Hamzah A, Sadeque Jafor, Jhaveri Sharan, Avanthika Chaithanya, Arisoyin Abimbola E, Dhanani Maulik B, Rath Swaroopa M

机构信息

Radiology, Massachusetts General Hospital, Boston, USA.

School of Medicine, Hashemite University, Zarqa, JOR.

出版信息

Cureus. 2021 Dec 28;13(12):e20776. doi: 10.7759/cureus.20776. eCollection 2021 Dec.

DOI:10.7759/cureus.20776
PMID:35111461
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8794413/
Abstract

Non-alcoholic fatty liver disease (NAFLD) refers to a spectrum of diseases involving the deposition of fat in the hepatocytes of people with little to no alcohol consumption. NAFLD is associated with hypertension, diabetes, obesity, etc. As their prevalence increases, the propensity and severity of NAFLD might increase. As per the recently developed multi-hit hypothesis, factors like oxidative stress, genetic predisposition, lipotoxicity, and insulin resistance have been found to play a key role in the development of NAFLD and its associated complications. This article focuses on NAFLD, its pathophysiology, risk factors, and the various genetic and epigenetic factors involved in its development along with possible treatment modalities. We conducted an all-language literature search on Medline, Cochrane, Embase, and Google Scholar until October 2021. The following search strings and Medical Subject Heading (MeSH) terms were used: "NAFLD," "NASH," "Fibrosis," and "Insulin Resistance." We explored the literature on NAFLD for its epidemiology, pathophysiology, the role of various genes, and how they influence the disease and associated complications about the disease and its hepatic and extrahepatic complications. With its rapidly increasing prevalence rates across the world and serious complications like NASH and hepatocellular carcinoma, NAFLD is becoming a major public health issue and more research is needed to formulate better screening tools and treatment protocols.

摘要

非酒精性脂肪性肝病(NAFLD)是指一系列疾病,涉及几乎不饮酒或不饮酒人群的肝细胞内脂肪沉积。NAFLD与高血压、糖尿病、肥胖等有关。随着它们的患病率增加,NAFLD的倾向和严重程度可能会增加。根据最近提出的多重打击假说,氧化应激、遗传易感性、脂毒性和胰岛素抵抗等因素在NAFLD及其相关并发症的发生发展中起着关键作用。本文重点关注NAFLD、其病理生理学、危险因素、参与其发生发展的各种遗传和表观遗传因素以及可能的治疗方式。我们在Medline、Cochrane、Embase和谷歌学术上进行了全语言文献检索,直至2021年10月。使用了以下检索词和医学主题词(MeSH):“NAFLD”、“NASH”、“纤维化”和“胰岛素抵抗”。我们查阅了关于NAFLD的文献,以了解其流行病学、病理生理学、各种基因的作用,以及它们如何影响该疾病及其相关并发症,包括肝脏和肝外并发症。由于NAFLD在全球的患病率迅速上升,以及诸如NASH和肝细胞癌等严重并发症,它正成为一个主要的公共卫生问题,需要更多的研究来制定更好的筛查工具和治疗方案。

相似文献

1
Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).预测非酒精性脂肪性肝病(NAFLD)进展的因素。
Cureus. 2021 Dec 28;13(12):e20776. doi: 10.7759/cureus.20776. eCollection 2021 Dec.
2
Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.植物疗法作为一种多靶点治疗方法应对非酒精性脂肪性肝病的多种病理生理学:实验干预的系统评价。
Medicina (Kaunas). 2021 Aug 14;57(8):822. doi: 10.3390/medicina57080822.
3
Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).非酒精性脂肪性肝病(NAFLD)/非酒精性脂肪性肝炎(NASH)的分子机制。
Adv Exp Med Biol. 2021;1261:223-229. doi: 10.1007/978-981-15-7360-6_20.
4
Non-alcoholic fatty liver disease.非酒精性脂肪性肝病。
Crit Rev Clin Lab Sci. 2011 May-Jun;48(3):97-113. doi: 10.3109/10408363.2011.596521.
5
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的临床流行病学和疾病负担。
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263.
6
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.新兴和成熟的非酒精性脂肪性肝病治疗方法。
Clin Ther. 2021 Sep;43(9):1476-1504. doi: 10.1016/j.clinthera.2021.07.013. Epub 2021 Aug 24.
7
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.非酒精性脂肪性肝炎:发病机制与新型治疗方法。
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:68-76. doi: 10.1111/jgh.12212.
8
Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD).遗传和表观遗传疾病修饰因子:非酒精性脂肪性肝病(NAFLD)和酒精性肝病(ALD)。
Transl Gastroenterol Hepatol. 2021 Jan 5;6:2. doi: 10.21037/tgh.2019.09.06. eCollection 2021.
9
Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病
Adv Exp Med Biol. 2017;960:443-467. doi: 10.1007/978-3-319-48382-5_19.
10
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.系统评价:成人非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学和自然史。
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30.

引用本文的文献

1
Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study.利拉鲁肽可减轻非糖尿病肥胖患者的肝脏脂肪变性并改善代谢指标:一项为期3个月的前瞻性研究。
Int J Mol Sci. 2025 Jun 19;26(12):5883. doi: 10.3390/ijms26125883.
2
The role of ubiquitination and deubiquitination in the pathogenesis of non-alcoholic fatty liver disease.泛素化与去泛素化在非酒精性脂肪性肝病发病机制中的作用
Front Immunol. 2025 Apr 11;16:1535362. doi: 10.3389/fimmu.2025.1535362. eCollection 2025.
3
Effectiveness of body roundness index for the prediction of nonalcoholic fatty liver disease: a systematic review and meta-analysis.身体圆润度指数预测非酒精性脂肪性肝病的有效性:一项系统评价和荟萃分析
Lipids Health Dis. 2025 Mar 27;24(1):117. doi: 10.1186/s12944-025-02544-3.
4
Influence of Varied Dietary Cholesterol Levels on Lipid Metabolism in Hamsters.不同膳食胆固醇水平对仓鼠脂代谢的影响。
Nutrients. 2024 Jul 30;16(15):2472. doi: 10.3390/nu16152472.
5
Single-Nucleotide Polymorphisms in Base-Excision Repair-Related Genes Involved in the Risk of an Occurrence of Non-Alcoholic Fatty Liver Disease.碱基切除修复相关基因单核苷酸多态性与非酒精性脂肪性肝病发病风险的关系。
Int J Mol Sci. 2023 Jul 11;24(14):11307. doi: 10.3390/ijms241411307.
6
Serum microRNA Levels as a Biomarker for Diagnosing Non-Alcoholic Fatty Liver Disease in Chinese Colorectal Polyp Patients.血清 microRNA 水平作为中国结直肠息肉患者非酒精性脂肪肝诊断的生物标志物。
Int J Mol Sci. 2023 May 22;24(10):9084. doi: 10.3390/ijms24109084.
7
Non-Alcoholic Fatty Liver Disease and Bone Tissue Metabolism: Current Findings and Future Perspectives.非酒精性脂肪性肝病与骨组织代谢:现有研究结果与未来展望。
Int J Mol Sci. 2023 May 8;24(9):8445. doi: 10.3390/ijms24098445.
8
Endogenous -3 PUFAs Improve Non-Alcoholic Fatty Liver Disease through FFAR4-Mediated Gut-Liver Crosstalk.内源性 -3PUFAs 通过 FFAR4 介导的肠-肝串扰改善非酒精性脂肪性肝病。
Nutrients. 2023 Jan 22;15(3):586. doi: 10.3390/nu15030586.
9
Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter.使用具有受控衰减参数的振动控制瞬时弹性成像技术对炎症性肠病患者进行肝脂肪变性和纤维化筛查。
J Clin Med. 2022 Oct 9;11(19):5959. doi: 10.3390/jcm11195959.
10
Targeting mitochondrial quality control of T cells: Regulating the immune response in HCC.靶向T细胞的线粒体质量控制:调节肝癌中的免疫反应。
Front Oncol. 2022 Sep 23;12:993437. doi: 10.3389/fonc.2022.993437. eCollection 2022.

本文引用的文献

1
The role of Sirtuin 2 in sustaining functional integrity of the liver.Sirtuin 2 在维持肝脏功能完整性中的作用。
Life Sci. 2021 Nov 15;285:119997. doi: 10.1016/j.lfs.2021.119997. Epub 2021 Sep 28.
2
Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis.脂肪变性和脂肪性肝炎患者血清中微小RNA谱分析
Front Cell Dev Biol. 2021 Sep 9;9:736677. doi: 10.3389/fcell.2021.736677. eCollection 2021.
3
Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD.非酒精性脂肪性肝病纤维化进展过程中 DNA 甲基化差异和细胞类型比例变化。
Clin Epigenetics. 2021 Aug 5;13(1):152. doi: 10.1186/s13148-021-01129-y.
4
Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests.线粒体的重要性:非酒精性脂肪性肝病(NAFLD)的系统方面和通过稳定同位素动态呼吸试验对肝功能的诊断评估。
Int J Mol Sci. 2021 Jul 19;22(14):7702. doi: 10.3390/ijms22147702.
5
Evaluating causality of cellular senescence in non-alcoholic fatty liver disease.评估细胞衰老在非酒精性脂肪性肝病中的因果关系。
JHEP Rep. 2021 May 1;3(4):100301. doi: 10.1016/j.jhepr.2021.100301. eCollection 2021 Aug.
6
Epigenetic Regulation of Peroxisome Proliferator-Activated Receptor Gamma Mediates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease.过氧化物酶体增殖物激活受体 γ 的表观遗传调控介导高脂肪饮食诱导的非酒精性脂肪性肝病。
Cells. 2021 May 31;10(6):1355. doi: 10.3390/cells10061355.
7
Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk.线粒体突变与决定非酒精性脂肪性肝病风险的遗传因素
Int J Mol Sci. 2021 Apr 24;22(9):4459. doi: 10.3390/ijms22094459.
8
Study of Cellular Senescence and Vitamin D Deficiency in Nonalcoholic Fatty Liver Disease and The Potential Protective Effect of Vitamin D Supplementation.非酒精性脂肪性肝病中细胞衰老与维生素D缺乏的研究及维生素D补充的潜在保护作用
J Clin Exp Hepatol. 2021 Mar-Apr;11(2):219-226. doi: 10.1016/j.jceh.2020.07.003. Epub 2020 Jul 18.
9
Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease.外显子组关联研究发现丙氨酸氨基转移酶在 GPAM 和 APOE 中的序列变异与脂肪性肝病相关。
Gastroenterology. 2021 Apr;160(5):1634-1646.e7. doi: 10.1053/j.gastro.2020.12.023. Epub 2021 Feb 6.
10
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments.非酒精性脂肪性肝炎:其发病机制、模型及医学治疗的综述
Front Pharmacol. 2020 Dec 3;11:603926. doi: 10.3389/fphar.2020.603926. eCollection 2020.